All lobbying filings

AVENUE SOLUTIONS

Lobbying for JAZZ PHARMACEUTICALS, INC. · Specialty pharmaceuticals

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 2

Health Issues

Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing, including orphan drugs; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders

Medicare/Medicaid

Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.